Adenoviral vector-based foot-and-mouth disease vaccine
US8323663B2 · kind B2 · utility
4Cited by
56References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2008 |
| Grant date | Dec 4, 2012 |
| Priority date | — |
| Expiry date | Jul 10, 2028 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A40/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.